Specialty Vision is an online directory, not a healthcare provider. Listed practices are not owned or operated by us.

Specialty Vision is an online directory and does not provide healthcare services. Listed practices and doctors are not owned, operated, or employed by Specialty Vision.

Autoimmune Retinopathy: Protecting Your Vision

Understanding Autoimmune Retinopathy

Understanding Autoimmune Retinopathy

Autoimmune retinopathy (AIR) occurs when the immune system produces antibodies that target proteins in the retina. These antiretinal antibodies damage photoreceptors, the specialized cells responsible for converting light into the signals your brain interprets as vision. Over time, this immune-mediated damage leads to progressive retinal degeneration and worsening vision.

AIR is considered rare. It accounts for a very small fraction of all cases seen at specialized uveitis and ocular immunology clinics (PMC, National Library of Medicine, 2014). Most uveitis specialists report seeing only one to three AIR patients per year (American Uveitis Society Survey, PMC, 2018).

There are two main categories of autoimmune retinopathy. The first is paraneoplastic AIR, which is linked to an underlying cancer. This category includes cancer-associated retinopathy (CAR), most often connected to small-cell lung cancer or breast cancer. It also includes melanoma-associated retinopathy (MAR), which occurs in patients with melanoma.

The second category is non-paraneoplastic AIR (npAIR), which occurs without any associated cancer. In npAIR, the immune system attacks retinal proteins due to a process called molecular mimicry. This happens when the immune system confuses retinal proteins with foreign substances such as bacterial or viral antigens.

In autoimmune retinopathy, the immune system creates antibodies against specific retinal proteins. The most commonly identified targets include recoverin, alpha-enolase, and carbonic anhydrase II. These antibodies bind to photoreceptors and trigger apoptosis (programmed cell death). This cell death occurs through pathways involving enzymes called caspases and an influx of calcium into cells. As more photoreceptors are destroyed, vision progressively declines.

Who Is Affected and Risk Factors

Non-paraneoplastic autoimmune retinopathy is more common in women, who make up 63% to 66% of diagnosed cases (AAO EyeWiki). The condition typically develops between the ages of 50 and 60, though it can occur at other ages as well.

People with a personal or family history of autoimmune diseases face a higher risk of developing AIR. Hypothyroidism (underactive thyroid) is one of the most commonly associated conditions. Patients with npAIR frequently have other autoimmune disorders as well. A history of autoimmune disease in close family members may also increase susceptibility.

For paraneoplastic forms of AIR, the primary risk factor is an underlying malignancy. Cancers most commonly associated with this condition include:

  • Small-cell lung cancer
  • Breast cancer
  • Melanoma
  • Gynecologic cancers

In paraneoplastic AIR, tumors produce proteins that resemble retinal proteins. The immune system attacks the tumor but also mistakenly targets the retina in the process.

The presence of antiretinal antibodies alone does not confirm a diagnosis of AIR. These antibodies can also be found in healthy individuals and in patients with other retinal conditions. A retina specialist must consider the full clinical picture before making a diagnosis. This includes symptoms, imaging results, and specialized testing.

Signs and Symptoms

Autoimmune retinopathy typically causes a range of visual symptoms that may develop suddenly or over weeks to months. Common symptoms include:

  • Unexplained vision loss affecting both eyes
  • Photopsias (flashing lights in your vision)
  • Scotomas (blind spots or missing areas in your visual field)
  • Nyctalopia (difficulty seeing in dim or dark environments)
  • Photoaversion (increased sensitivity to light)
  • Decreased color vision

One of the most confusing aspects of AIR is that the retina may appear completely normal during a standard eye exam. This is especially true in the early stages. Unlike many retinal conditions that produce visible changes such as bleeding or swelling, AIR can cause significant vision loss with a normal-appearing fundus (back of the eye). This means symptoms may initially be attributed to other causes or even dismissed.

If you experience sudden vision loss in one or both eyes, a rapid increase in flashing lights, or new blind spots in your vision, see a retina specialist or go to the emergency room immediately. These symptoms can indicate serious retinal damage that requires prompt evaluation. Early detection of AIR may improve the chances of preserving remaining vision.

Diagnosis and Testing

Diagnosing autoimmune retinopathy requires a thorough evaluation by a retina specialist experienced in inflammatory and immune-mediated retinal diseases. The specialist will review your complete medical history. Close attention is paid to any history of autoimmune conditions or cancer. A detailed eye examination will assess visual acuity, color vision, and the overall appearance of the retina.

Electroretinography (ERG) is one of the most important tests in diagnosing AIR. This test measures the electrical responses of photoreceptors and other retinal cells when stimulated by light. In autoimmune retinopathy, the ERG typically shows reduced or abnormal responses. This indicates photoreceptor dysfunction. The pattern of abnormality can help distinguish AIR from other retinal degenerative conditions.

Multimodal imaging plays a key role in evaluating AIR. Optical coherence tomography (OCT), a non-invasive scan that creates detailed cross-sectional images of the retina, often reveals disruption of the ellipsoid zone. This layer represents the photoreceptor cells, and damage to it correlates with vision loss. Fundus autofluorescence (FAF) may show characteristic patterns including parafoveal hyperautofluorescent rings. These bright rings around the central retina suggest ongoing photoreceptor stress.

Blood tests can detect circulating antiretinal antibodies. However, the presence of these antibodies alone is not enough to confirm a diagnosis. In 2025, the American Academy of Ophthalmology published new diagnostic guidelines that categorize AIR as 'probable,' 'possible,' or 'unlikely' based on specific clinical criteria (AAO, 2025). This framework helps retina specialists make more consistent and accurate diagnoses.

When autoimmune retinopathy is suspected, a retina specialist may recommend cancer screening. This is particularly important if the clinical presentation is consistent with paraneoplastic AIR. Screening may involve imaging studies, blood work, and referrals to oncologists. Identifying and treating an underlying malignancy is a critical part of managing paraneoplastic forms of the condition.

Treatment Options

There is currently no known way to reverse autoimmune retinopathy. The primary goals of treatment are to slow or stop the immune attack on the retina, stabilize vision, and preserve as much remaining sight as possible. Treatment approaches are largely based on clinical experience and emerging research. A retina specialist will tailor a treatment plan based on the type and severity of AIR.

Corticosteroids are often used as an initial treatment to reduce inflammation and suppress the immune response. These may be given as oral medications (such as prednisone), injections around or into the eye, or as sustained-release implants. While corticosteroids can provide short-term improvement, long-term use carries risks. These include elevated eye pressure, cataracts, and systemic side effects. They are typically used as a bridge to longer-term immunosuppressive therapy.

For ongoing management, retina specialists may prescribe steroid-sparing immunosuppressive medications. These drugs work by broadly reducing the activity of the immune system to prevent further retinal damage. Commonly used medications include:

  • Mycophenolate mofetil
  • Azathioprine
  • Cyclosporine

These medications require regular monitoring through blood tests to check for side effects. It may take several weeks for their full effect to develop.

Intravenous immunoglobulin (IVIG) is a treatment in which concentrated antibodies from donated blood are infused into a vein. IVIG can help modulate the immune system and has been used in some patients with AIR. This treatment is typically administered in a clinical setting and may require repeated infusions over time.

Newer biologic medications offer more targeted immune suppression. Rituximab, a medication that targets B cells (the immune cells that produce antibodies), has shown promise in stabilizing or improving visual acuity in many AIR patients. Anti-interleukin-6 agents such as tocilizumab and sarilumab have also shown encouraging results, particularly for npAIR patients who develop cystoid macular edema (swelling in the central retina). In studies of these agents, 25% of treated eyes showed resolution of macular edema, and 40% of eyes improved by two or more lines on the vision chart (PMC, National Library of Medicine).

What to Expect

Autoimmune retinopathy is a chronic condition that varies significantly from person to person. Some patients experience a relatively stable course with treatment. Others may have progressive vision loss despite therapy. The response to immunosuppressive treatment can take weeks to months to become apparent. Regular follow-up visits are essential to monitor retinal response and adjust treatment as needed.

Patients with AIR typically need frequent visits to a retina specialist, especially in the early stages of treatment. Follow-up appointments may include repeat ERG testing, OCT scans, visual field tests, and fundus autofluorescence imaging. These tests help track changes in photoreceptor function and retinal structure over time. Blood work may also be needed to monitor for side effects of immunosuppressive medications.

It is important to understand that treatment for AIR aims to preserve existing vision rather than restore vision that has been lost. Photoreceptors destroyed by the immune response generally do not regenerate. Starting treatment early, before extensive photoreceptor loss has occurred, offers the best chance of maintaining useful vision. Your retina specialist will discuss realistic goals based on your specific situation.

Living With Autoimmune Retinopathy

Living with AIR may require practical adjustments depending on the degree of vision loss. Low vision aids such as magnifiers, high-contrast displays, and specialized lighting can help with daily tasks like reading and cooking. A low vision rehabilitation specialist can assess your needs and recommend tools and strategies to make the most of your remaining vision.

Coping with a rare, chronic condition that affects vision can be emotionally challenging. Feelings of frustration, anxiety, or grief over vision loss are normal. Support groups for people with rare eye diseases can provide connection with others who understand the experience. Mental health professionals who specialize in chronic illness can also be a valuable resource.

Because AIR often occurs alongside other autoimmune conditions, coordinated care among multiple specialists is often necessary. It may also be linked to cancer in paraneoplastic forms. Your retina specialist may work with rheumatologists, oncologists, and other physicians. Keeping all of your healthcare providers informed about your treatments helps ensure the best possible outcomes.

When to See a Retina Specialist

You should see a retina specialist if you experience unexplained vision loss in both eyes, new or worsening blind spots, or difficulty seeing at night. Flashing lights or a noticeable decrease in color vision also warrant evaluation. These symptoms are especially concerning if you have a history of autoimmune disease or cancer. Specialized testing is often needed to identify AIR because it can progress without obvious visible changes.

Early diagnosis and treatment of autoimmune retinopathy give the best chance of preserving vision. If your optometrist or general ophthalmologist suspects AIR, they should refer you to a retina specialist with experience in inflammatory and immune-mediated retinal diseases. Because the condition is rare, seeking care at a center familiar with AIR can make a significant difference in diagnosis accuracy and treatment effectiveness.

Questions and Answers

In many cases, the retina may appear normal during a standard eye exam, especially early in the disease. This is one reason AIR can be difficult to diagnose. Specialized tests such as electroretinography, optical coherence tomography, and antiretinal antibody testing are usually needed. If you have symptoms like unexplained vision loss or night blindness, let your eye care provider know so they can consider further testing or referral to a retina specialist.

No, although both conditions involve the immune system affecting the eye, they are distinct. Uveitis involves visible inflammation inside the eye. Autoimmune retinopathy typically occurs with little or no intraocular inflammation. The hallmark of AIR is immune-mediated damage to photoreceptors driven by antiretinal antibodies. However, retina specialists who treat uveitis and ocular immunology conditions are often the most experienced in managing AIR.

Many patients with autoimmune retinopathy require long-term immunosuppressive treatment to keep the condition stable. The duration and intensity of treatment depend on retinal response and immune activity control. Some patients may eventually taper their medications under close supervision. Others may need ongoing therapy. Your retina specialist will work with you to determine the most appropriate long-term management plan.

Not necessarily. Antiretinal antibodies have been found in healthy individuals and in people with other retinal conditions. The presence of these antibodies is just one piece of the diagnostic puzzle. A retina specialist will consider your symptoms, imaging findings, ERG results, and overall medical history. The 2025 AAO diagnostic framework helps classify cases as probable, possible, or unlikely based on a combination of these factors.

Not in most cases. Non-paraneoplastic AIR, the more common form, occurs without any associated malignancy. However, because paraneoplastic AIR is linked to certain cancers, a retina specialist may recommend cancer screening at diagnosis. This is especially important if your symptoms developed rapidly or if you have other risk factors for malignancy. If cancer is identified, treating it is an essential part of managing the retinopathy.

Specialty Vision
Privacy Overview